Answers are grounded in this paper and cite their sources.
Ovarian cancer (OC) is a major cause of cancer-related mortality among women worldwide, mainly because most cases are diagnosed at advanced stages due to non-specific early symptoms. Although early detection is essential for improving clinical outcomes, accurate and accessible screening remains a major challenge, owing to the non-specific nature of early symptoms, the pronounced histological and molecular heterogeneity of the disease, and the poor performance of conventional screening approaches based on cancer antigen 125 (CA-125), human epididymis protein 4 (HE4) and imaging modalities. This review outlines the major biological and technical challenges in the early diagnosis of OC, briefly summarizes the value and limitations of conventional diagnostic approaches and focuses on current progress in emerging biomarkers, including circulating tumour DNA (ctDNA)/cell-free DNA (cfDNA) alterations, exosomal biomarkers and mesothelin multi-marker combined detection strategies, and novel technologies, such as artificial intelligence, nanotechnology, single-cell sequencing and biosensors for early detection. We also discuss the advantages, current limitations, practical considerations and translational barriers of these approaches. Future advances in OC screening will require the integration of sensitive biomarkers, multimodal detection strategies and more accessible, cost-effective technologies to improve early diagnosis and patient survival.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: